Theo Trandafirescu
Pulmonary Disease · Bayside, NYNPI 1154490514
Payments from drug & device makers
Across 64 payments — averaging $40.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$668
- E.r. Squibb & Sons, L.L.C.$604
- Pfizer$336
- Genentech USA, Inc.$164
- Boehringer Ingelheim$143
- Novartis$138
- plus $557 from 10 others
What the payments were for
- Food & beverage$2,610100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $668 |
| E.r. Squibb & Sons, L.L.C. | 25 | $604 |
| Pfizer | 10 | $336 |
| Genentech USA, Inc. | 2 | $164 |
| Boehringer Ingelheim | 2 | $143 |
| Novartis | 2 | $138 |
| AstraZeneca | 3 | $136 |
| United Therapeutics Corporation | 1 | $123 |
| Johnson & Johnson(2 entities) | 4 | $92 |
| Intuitive Surgical | 1 | $72 |
| Merck | 2 | $33 |
| Shionogi Inc | 1 | $23 |
| AbbVie | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Gilead | 1 | $17 |
| Edwards Lifesciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,610 in reported general payments places this provider in the 60th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $54,204 |
| OzempicSemaglutide | 11 | $10,715 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,059 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,181 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,596 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,378 |
| Montelukast Sodium | 23 | $523 |
| Pantoprazole Sodium | 24 | $301 |
| Fluticasone Propionate | 29 | $272 |
| Losartan Potassium | 16 | $188 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bayside
- Jack MannBayside$966K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.